WeTrials
Recruiting

A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)

What is this study?

This study is testing new combinations of medications, including an investigational drug called Dato-DXd, compared to standard chemotherapy for people with advanced lung cancer. The goal is to find better treatment options when current therapies stop working.

Who can participate?

You may be able to join if you have a specific type of advanced lung cancer with certain gene mutations, and your cancer has grown while taking a medication called osimertinib. Doctors will also check your overall health and medical history to make sure the study is safe for you.

What will happen?

Participants will be randomly chosen to receive either the study medications or standard chemotherapy. Your health and tumor growth will be closely monitored through regular scans and check-ups throughout the process.

Where and when?

This study is currently recruiting participants at multiple locations, including sites in Arkansas and California. You can talk to your care team to see if a location near you is participating.

Key Points
  • 1Tests new cancer treatments against standard chemotherapy
  • 2For patients whose lung cancer progressed on osimertinib
  • 3Currently recruiting patients at select medical centers

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Metastatic Non-small Cell Lung Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.